>
The Download: GLOBAL WAR LOOMING, GOVERNMENT AT YOUR DOOR & DOCTORS...
Episode 495: AI'S FREE PASS, NIH FINALLY WAKES UP & CHILDHOOD DEATH BOMBSHELL
Xi backs AI safety with Trump, draws Taiwan line, urges Iran talks
The Israeli Lobby Boasts of Its Rule of America
Tesla Model 3 killer charges from 10 to 97% in just 9 minutes
World-first unpowered DNA computer sets speed record
I Power 5 Buildings Off-Grid. Here's How
The US government is pushing hard to get a working nuclear fission reactor into space by late 2028
SpaceX Starmind AI in Space Radiator
China Will Dominate Global Nuclear Energy Through 2035, Analyst Says
These Absolutely Wild-Looking EVs Are Saudi Arabia's First Homegrown Cars
BEYOND THE MOON: NASA plans a nuclear-powered fleet to push DEEPER into space
Big Oil Backs Mazama's $135 Million Bet On Superhot Geothermal

Full regeneration and immortalized cells exists in humans two weeks after conception.
There is work to re-activate those capabilities with adult cells.
The video and screenshots below are from the the CEO of AgeX Dr Michael West and another with Michael West talking with Dr. Aubrey de Grey, V.P. New Technology Discovery.
AgeX Therapeutics is a biotechnology company formed in 2017 as a subsidiary of BioTime, Inc (NYSE MKT: BTX). Its mission is to apply technology related to cell immortality and pluripotency to human aging and age-related disease. The Company's technology platform has three facets: Pluripotent stem cell-derived progenitor cell lines representing over 200 types of cells in the body (PureStem technology); HyStem matrices; and induced tissue regeneration (iTR) – the latter being an emerging technology directed at inducing the immortal regeneration of tissues in the body.